Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.

Publication Title

Annals of the rheumatic diseases

Authors

Philip Mease, Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, Washington, USA.Follow
Désirée van der Heijde
Robert Landewé
Shephard Mpofu
Proton Rahman
Hasan Tahir
Atul Singhal
Elke Boettcher
Sandra Navarra
Karin Meiser
Aimee Readie
Luminita Pricop
Ken Abrams

Document Type

Article

Publication Date

6-1-2018

Keywords

cytokines; dmards (biologic); psoriatic arthritis; treatment

Abstract

OBJECTIVES: To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic progression in patients with psoriatic arthritis (PsA).

METHODS: Adults (n=996) with active PsA were randomised 2:2:2:3 to s.c. secukinumab 300 mg or 150 mg with loading dose (LD), 150 mg without LD or placebo. All groups received secukinumab or placebo at baseline, weeks 1, 2 and 3 and then every 4 weeks from week 4. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response at week 16.

RESULTS: Significantly more patients achieved an ACR20 response at week 16 with secukinumab 300 mg with LD (62.6%), 150 mg with LD (55.5%) or 150 mg without LD (59.5%) than placebo (27.4%) (p

CONCLUSION: S.c. secukinumab 300 mg and 150 mg with and without LD significantly improved clinical signs and symptoms and inhibited radiographic structural progression versus placebo at week 24 in patients with PsA.

TRIAL REGISTRATION NUMBER: NCT02404350; Results.

Clinical Institute

Orthopedics & Sports Medicine

Specialty/Research Institute

Orthopedics

Specialty/Research Institute

Rheumatology